Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that in July 2025, it will initiate their first usability study of a medical device software ...

Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), the developer and ...

Agreement expands partnership between Medtronic and Cosmo Pharmaceuticals, set to transform endoscopy with cutting-edge AI technology DUBLIN, Dec. 11, 2023 /PRNewswire/ -- Medtronic plc (MDT) (NYSE: ...

Medtronic has entered a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices to further capitalize on the achievements of Medtronic’s GI Genius intelligent endoscopy ...

Cosmo Artificial Intelligence Ltd. received the FDA’s nod for its GI Genius intelligent endoscopy system. The device – the first of its kind, according to the agency – uses artificial intelligence (AI ...

Please provide your email address to receive an email when new articles are posted on . Mean number of adenomas per procedure was higher with GI Genius vs. standard colonoscopy (1.56 vs. 1.21), as was ...

A strategic collaboration with Cosmo Pharmaceuticals and NVIDIA delivers the GI Genius™ AI Access™ platform designed to accelerate AI innovation for healthcare. Developed and manufactured by Cosmo ...

Through a virtual sandbox that simulates the GI Genius system, new AI developers can take their programs out for a spin before signing a distribution agreement with Medtronic. (Medtronic) Medtronic is ...

“This is what the future of medicine looks like: real-time AI, embedded naturally into the physician’s workflow by blending digital content with the physical world,” said Cosmo CEO Giovanni Di Napoli.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Use of GI Genius increased mean adenomas per colonoscopy ...